Because of the fact that CTLA-4 and PD-1 play a crucial regulatory role in tumor immunoreaction process, their inhibitors have been well studied for a long period and demonstrated exciting benefit in clinical cancer therapy. This evidence concerns the gene CTLA4 and neoplasm.